Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 4/20 | 0.74 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1005421 | 0.86 | VCAM1 (1.00) | VCAM1XDHCYP19A1ALDH1A1CYP3A4 | |
| SCHEMBL7090977 | 0.86 | VCAM1 (0.91) | VCAM1XDHCYP19A1ALDH1A1GRIN2D | |
| SCHEMBL16951428 | 0.81 | VCAM1 (0.47) | VCAM1CYP19A1ALDH1A1CYP3A4 | |
| Acetonitrile SCHEMBL27788615 | 0.80 | VCAM1 (0.88) | VCAM1XDHCYP19A1ALDH1A1CYP3A4 | |
| Nitrogen SCHEMBL27917117 | 0.79 | CYP19A1 (0.56) | VCAM1CYP19A1ALDH1A1CYP3A4 | |
| SCHEMBL219410 | 0.79 | CYP19A1 (0.55) | VCAM1CYP19A1ALDH1A1CYP3A4 | |
| SCHEMBL1026447 | 0.79 | CYP19A1 (0.62) | VCAM1CYP19A1ALDH1A1CYP3A4 | |
| SCHEMBL2303201 | 0.77 | VCAM1 (0.74) | VCAM1XDHCYP19A1ALDH1A1GRIN2D | |
| SCHEMBL3771130 | 0.77 | VCAM1 (0.74) | VCAM1XDHCYP19A1ALDH1A1GRIN2D | |
| SCHEMBL1521510 | 0.77 | VCAM1 (0.74) | VCAM1XDHCYP19A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118459440-A | Preparation method and application of tetra-substituted aryl compound | 江苏普莱医药生物技术有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20240254093-A1 | GPR35 Agonist Compounds | NXERA PHARMA UK LIMITED (GB) | 2024-08-01 | — | — | US | disclosed |
| US-20240228482-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | HOTSPOT THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-117751115-A | Compounds, compositions, and methods of treating cancer | 热点治疗公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-4326708-A1 | GPR35 AGONIST COMPOUNDS | Heptares Therapeutics Limited (GB) | 2024-02-28 | — | — | EP | disclosed |
| CN-117529472-A | GPR35 agonist compounds | 赫普泰雅治疗有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-11833162-B2 | Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2023-12-05 | — | — | US | disclosed |
| EP-3700911-B1 | NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022224212-A1 | GPR35 AGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-10-27 | — | — | WO | disclosed |
| EP-3700911-A1 | NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Les Laboratoires Servier SAS (FR) | 2020-09-02 | — | — | EP | disclosed |
| US-8299267-B2 | (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating | COMENTIS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| WO-2012093101-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2012-07-12 | — | — | WO | disclosed |
| US-20100286170-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | COMENTIS, INC | 2010-11-11 | — | — | US | disclosed |
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| CN-101868457-A | (3-hydroxy-4-amino-but-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for use in therapy | COMENTIS INC | 2010-10-20 | — | — | CN | disclosed |
| CN-101821238-A | Suppress the active isophthaloyl sulfonamide derivatives of beta-secretase (BETA-SECRETASE) | COMENTIS INC | 2010-09-01 | — | — | CN | disclosed |
| EP-2205596-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | COMENTIS, INC. (US) | 2010-07-14 | — | — | EP | disclosed |
| EP-2178837-A2 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009042694-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | COMENTIS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009015369-A2 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11833162-B2 | Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same | C1R, F12, RDX | VCAM1 4489/4885XDH 487/4885CYP19A1 210/4885 |
| US-20240254093-A1 | GPR35 Agonist Compounds | GPR35, GPR119, GPR68 | VCAM1 2113/4885XDH 913/4885CYP19A1 478/4885 |
| US-20240228482-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | TP53, CASP3, BAX | VCAM1 2703/4885XDH 847/4885CYP19A1 275/4885 |
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | BACE1, BACE2, APP | VCAM1 3415/4885XDH 3097/4885CYP19A1 1830/4885 |
| US-20100286170-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | BACE1, BACE2, PSEN1 | VCAM1 2271/4885XDH 1768/4885CYP19A1 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.